New Infectious Disease Test Promises Quick Diagnosis
|
By LabMedica International staff writers Posted on 05 Jan 2016 |

Image: Colored Transmission electron micrograph of Clostridium difficile forming an endospore (red) (Photo courtesy of Dr. J. Thomas Lamont).
Early detection of specific pathogens has long been recognized as a vital strategy in the control of infectious diseases because it can lead to timely care of patients and prevent potential outbreaks.
The detection of specific bacteria represents a significant challenge because of the presence of many different species of bacteria in biological samples. Furthermore, for any given species of bacterium, only virulent strains are infectious while other strains of the same species may be harmless or even beneficial to human health.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) found a way to make DNAzymes, or single-stranded catalytic DNA molecules from a simple test tube technique that allows for isolation of rare DNA sequences with special functions. The team's first success was the development of a molecular probe that precisely recognizes the strain which caused the outbreak of Clostridium difficile infection in Hamilton, Ontario in 2011. This strain was very infectious, resistant to antibiotics and even fatal to some patients. Instead of having to do several different tests to narrow down to a positive identification of the specific strain, the scientists can now quickly pinpoint this superbug using their new molecular probe.
The team obtained an RNA-cleaving fluorogenic DNAzyme (RFD) that can recognize an infectious strain of C. difficile. This DNAzyme not only exhibits no cross-reactivity to other bacterial species, but also is highly strain-selective for C. difficile. The special DNAzyme (catalytic DNA), RFD-CD1, showed exquisite specificity for a pathogenic strain of C. difficile. RFD-CD1 was derived by an in vitro selection approach where a random-sequence DNA library was allowed to react with an unpurified molecular mixture derived from this strain of C. difficile, coupled with a subtractive selection strategy to eliminate cross-reactivities to unintended C. difficile strains and other bacteria species.
Bruno J. Salena, MD, an associate professor of medicine and coauthor of the study, said, “This technology can be extended to the further discovery of other superbug strain-specific pathogens. For example, such technology would prove useful in the identification of hypervirulent or resistant strains, implementation of the most appropriate strain-specific treatments and tracking of outbreaks.” The study was published on December 16, 2015, in the journal Angewandte Chemie International Edition.
Related Links:
McMaster University
The detection of specific bacteria represents a significant challenge because of the presence of many different species of bacteria in biological samples. Furthermore, for any given species of bacterium, only virulent strains are infectious while other strains of the same species may be harmless or even beneficial to human health.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) found a way to make DNAzymes, or single-stranded catalytic DNA molecules from a simple test tube technique that allows for isolation of rare DNA sequences with special functions. The team's first success was the development of a molecular probe that precisely recognizes the strain which caused the outbreak of Clostridium difficile infection in Hamilton, Ontario in 2011. This strain was very infectious, resistant to antibiotics and even fatal to some patients. Instead of having to do several different tests to narrow down to a positive identification of the specific strain, the scientists can now quickly pinpoint this superbug using their new molecular probe.
The team obtained an RNA-cleaving fluorogenic DNAzyme (RFD) that can recognize an infectious strain of C. difficile. This DNAzyme not only exhibits no cross-reactivity to other bacterial species, but also is highly strain-selective for C. difficile. The special DNAzyme (catalytic DNA), RFD-CD1, showed exquisite specificity for a pathogenic strain of C. difficile. RFD-CD1 was derived by an in vitro selection approach where a random-sequence DNA library was allowed to react with an unpurified molecular mixture derived from this strain of C. difficile, coupled with a subtractive selection strategy to eliminate cross-reactivities to unintended C. difficile strains and other bacteria species.
Bruno J. Salena, MD, an associate professor of medicine and coauthor of the study, said, “This technology can be extended to the further discovery of other superbug strain-specific pathogens. For example, such technology would prove useful in the identification of hypervirulent or resistant strains, implementation of the most appropriate strain-specific treatments and tracking of outbreaks.” The study was published on December 16, 2015, in the journal Angewandte Chemie International Edition.
Related Links:
McMaster University
Latest Technology News
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement

- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
- Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
- 3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
- Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
Urine Test Detects Early Stage Pancreatic Cancer
Pancreatic cancer remains among the hardest cancers to detect early. In the UK, around 10,000 people are diagnosed each year, but only 5% survive beyond five years. Late diagnosis is a major factor—more... Read more
Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








